Aug. 6 at 9:23 PM
$AVL Blacamesine acts as a high-affinity SIGMAR1 agonist, designed specifically to:
Restore cellular homeostasis
Reduce oxidative stress
Promote autophagy and synaptic repair
The fact that fluoxetine—a widely used antidepressant—acts via SIGMAR1 (and also improves cognitive deficits in Schizophrenia) REINFORCES the legitimacy of Anavex’s approach. BUT blarcamesine is far more targeted, potent, and designed for disease modification, not just symptom relief.